Alopecia Areata-Like Presentations With Mogamulizumab Therapy
September 2023
in “
JAAD case reports
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → 
Studysummary In this case report, mogamulizumab treatment for Sézary syndrome was associated with rashes and alopecia in a patient, highlighting the potential for immune-mediated side effects and suggesting that such adverse effects might indicate a favorable prognosis, though further studies are needed.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
Mogamulizumab, used for treating mycosis fungoides and Sézary syndrome, has been linked to alopecia areata-like presentations. A 71-year-old man with Sézary syndrome developed widespread alopecia and follicular dermatitis after treatment with mogamulizumab. Histopathology showed a predominance of CD8+ T-cells, indicating drug-induced alopecia. After discontinuing mogamulizumab, the patient's Sézary syndrome remained in remission, and his rash resolved. This suggests that mogamulizumab-associated alopecia may be a positive prognostic factor, though further studies are needed.
